Maintain ‘hold’ on Dr Reddy’s, target Rs 3,600: Jefferies

By: |
Updated: Nov 10, 2015 1:59 AM

We retain our ‘hold’ rating on the D. Reddy’s Laboratories (DRRD) stock. Earnings for the next 6-9 months will remain subdued in our view...

We retain our ‘hold’ rating on the Dr. Reddy’s Laboratories (DRRD) stock. Earnings for the next 6-9 months will remain subdued in our view as the company focuses on remedial work leading to supply disruptions. While the company has a strong R&D pipeline, the facility compliance will overshadow filings/pipeline in the near term in our view.

DRL announced that it has received warning letters for three of its facilities. The warning letter issued to DRRD is a major negative for the company due to two factors: Management had, post 1Q16 results, stated that they have completed the remedial work from their side and are awaiting a re-inspection. The warning letter, however, shows that the FDA considers DRRD’s response insufficient and the company needs to do much more to make the facilities compliant. Warning letters at three facilities indicates a potential risk that the issues are systemic to the company.
Post a facility inspection, FDA gives the Form 483, citing the deficiencies it has found. The company then has to respond and implement corrective measures to address these.

If FDA is not satisfied with the response and the corrective measures, it issues a warning letter, which does not restrict supplies from the plant but it stops any further approvals from the plant.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Mcap of 4 of top-10 valued firms jumps over Rs 1.15 lakh cr; RIL biggest gainer
2Markets may remain volatile in holiday-shortened week: Analysts
3Apollo Hospitals raises Rs 1,170 cr through allotment of shares to QIBs